Status: Not yet recruiting
Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients
This study aims to evaluate the efficacy and safety of DWP16001 in type 2 diabetic nephropathy with moderate renal impairment patients (CKD stage 3)
Participants needed: 348
Trial details
Phase: Phase 3Age: 19+Biological sex: AllType: InterventionalSponsor: Daewoong Pharmaceutical Co. LTD.Updated: Sep 20, 2024Locations: 1
Eligibility criteria
Men and women aged 19 years or older as of the date of written consent. [+8]
Individuals diagnosed with renal diseases other than diabetic chronic kidney dis... [+32]